Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$32.83M+1530.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Risser
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 293
- Beta
- 1.23
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.27
Financials
Revenue
$32.83M+1530.2%Net Income
$19.52MEBITDA
$-64.54MFree Cash Flow
$-41.55M-186.9%EPS (diluted)
$0.31Shares Outstanding (diluted)
63.59M+82.9%Operating Expenses
$0.00Cash & Debt
$173.31MReturn of Capital
$0.00Revenue by Segment (annual)
$139.81MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $149.50M | $-74.62M | $-1.18 |
| 2024 | $148.34M | $-66.97M | $-1.07 |
| 2023 | $57.19M | $-9.06M | $-0.15 |
| 2022 | $150.02M | $-119.76M | $-1.95 |
| 2021 | $75.64M | $-202.12M | $-3.37 |
| 2020 | $97.76M | $-129.74M | $-2.47 |
| 2019 | $62.02M | $-151.81M | $-3.16 |
| 2018 | $60.12M | $-171.45M | $-4.19 |
| 2017 | $155.52M | $-19.63M | $-0.54 |
| 2016 | $86.58M | $-58.53M | $-1.69 |
| 2015 | $100.85M | $-20.14M | $-0.63 |
| 2014 | $47.26M | $-38.31M | $-1.40 |
| 2013 | $56.75M | $-260.8K | $-0.01 |
| 2012 | $59.65M | $8.36M | $0.46 |
Valuation
MGNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103+14.81%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·26d ago·Neutral
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. Gilead's recent activity on multiple TCEs and MacroGenics' negative enterprise value suggest partnership is under appreciated & undervalued.
View source ↗ - Newszacks.com·53d ago·Negative
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.31 vs $-0.08beat
- Wed, May 13$-0.58 vs $-0.57miss
- Mon, Mar 9$-0.22 vs $-0.42beat
- Wed, Nov 12$0.27 vs $-0.48beat
- Thu, Aug 14$-0.57 vs $-0.59beat
- Tue, May 13$-0.65 vs $-0.61miss
Estimates and results for MGNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MGNX officers and directors.
- Bought
- —
- Sold
- $129k
0 trades
1 trade
- Peters Jeffrey Stuartsold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MGNX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.